AR130641A1 - Anticuerpos anti-cd28 - Google Patents
Anticuerpos anti-cd28Info
- Publication number
- AR130641A1 AR130641A1 ARP230102621A ARP230102621A AR130641A1 AR 130641 A1 AR130641 A1 AR 130641A1 AR P230102621 A ARP230102621 A AR P230102621A AR P230102621 A ARP230102621 A AR P230102621A AR 130641 A1 AR130641 A1 AR 130641A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- antigen
- antibody
- sequence
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C07K16/106—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a CD28, que comprende un dominio variable único de inmunoglobulina (IVSD) que comprende una secuencia de CDR-H1, una secuencia de CDR-H2, y una secuencia de CDR-H3. Una molécula de ácido nucleico aislada que codifica el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones anteriores. Un vector de expresión que comprende la molécula de ácido nucleico de la reivindicación 13. Una célula huésped que comprende el vector de expresión de la reivindicación 14. Un método para inhibir la actividad de CD28 en un sujeto, que comprende administrar a un sujeto el anticuerpo o fragmento de unión a antígeno del mismo según una cualquiera de las reivindicaciones 1 - 12, inhibiendo de esta manera la actividad de CD28 en el sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22315222 | 2022-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130641A1 true AR130641A1 (es) | 2024-12-18 |
Family
ID=83903228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102621A AR130641A1 (es) | 2022-09-30 | 2023-09-29 | Anticuerpos anti-cd28 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250340642A1 (es) |
| EP (1) | EP4593960A1 (es) |
| JP (1) | JP2025532700A (es) |
| KR (1) | KR20250075698A (es) |
| CN (1) | CN120129698A (es) |
| AR (1) | AR130641A1 (es) |
| AU (1) | AU2023348293A1 (es) |
| CO (1) | CO2025005325A2 (es) |
| IL (1) | IL319891A (es) |
| MX (1) | MX2025003723A (es) |
| TW (1) | TW202430561A (es) |
| WO (1) | WO2024068944A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202544034A (zh) * | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420178T1 (de) | 1992-08-21 | 2009-01-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU2152299A (en) | 1997-10-27 | 1999-05-24 | Unilever Plc | Multivalent antigen-binding proteins |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| EP4097129A1 (en) * | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| US12448449B2 (en) * | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
-
2023
- 2023-09-28 TW TW112137522A patent/TW202430561A/zh unknown
- 2023-09-29 KR KR1020257013996A patent/KR20250075698A/ko active Pending
- 2023-09-29 AU AU2023348293A patent/AU2023348293A1/en active Pending
- 2023-09-29 AR ARP230102621A patent/AR130641A1/es unknown
- 2023-09-29 CN CN202380069840.0A patent/CN120129698A/zh active Pending
- 2023-09-29 IL IL319891A patent/IL319891A/en unknown
- 2023-09-29 WO PCT/EP2023/077092 patent/WO2024068944A1/en not_active Ceased
- 2023-09-29 JP JP2025518482A patent/JP2025532700A/ja active Pending
- 2023-09-29 EP EP23783356.1A patent/EP4593960A1/en active Pending
-
2025
- 2025-03-14 US US19/079,824 patent/US20250340642A1/en active Pending
- 2025-03-27 MX MX2025003723A patent/MX2025003723A/es unknown
- 2025-04-28 CO CONC2025/0005325A patent/CO2025005325A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025003723A (es) | 2025-07-01 |
| CO2025005325A2 (es) | 2025-05-19 |
| EP4593960A1 (en) | 2025-08-06 |
| TW202430561A (zh) | 2024-08-01 |
| KR20250075698A (ko) | 2025-05-28 |
| US20250340642A1 (en) | 2025-11-06 |
| CN120129698A (zh) | 2025-06-10 |
| IL319891A (en) | 2025-05-01 |
| WO2024068944A1 (en) | 2024-04-04 |
| JP2025532700A (ja) | 2025-10-01 |
| AU2023348293A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. | |
| AR130641A1 (es) | Anticuerpos anti-cd28 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät |